FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4379283222> ?p ?o ?g. }

• W4379283222 endingPage "TPS2670" @default.
• W4379283222 startingPage "TPS2670" @default.
• W4379283222 abstract "TPS2670 Background: Claudin-18.2 (CLDN18.2), whose expression is normally restricted to short-lived gastric epithelial cells, is ectopically expressed in tumors with unmet needs such as gastric, gastroesophageal junction (GEJ), pancreatic, ovarian, and biliary tract tumors. CLDN18.2 has thus emerged as a promising target for therapeutic antibody development. BNT141 is a novel RNA-based therapeutic that comprises two pseudouridine-modified mRNAs encapsulated in lipid nanoparticles. Upon intravenous injection, BNT141 is preferentially taken up by the liver where RNAs are translated and released into the circulation as fully assembled anti-CLDN18.2 antibodies. The resulting antibody is sequence identical to IMAB362, a CLDN18.2-targeted antibody that provided clinical benefit as an add-on to chemotherapy in the Phase III SPOTLIGHT trial (Shitara et al. J Clin Oncol. 2023). RNA-encoded antibodies can be developed more rapidly compared with recombinant antibodies and have the potential for favorable PK/PD properties and improved tolerability. Methods: This is a Phase I/II, open-label, multisite, dose escalation and expansion trial to examine safety, efficacy, and PK/PD of BNT141 in patients with CLDN18.2+ tumors (NCT04683939). The trial comprises 3 parts: dose escalation with BNT141 as monotherapy, dose escalation with BNT141 in combination with nab-paclitaxel and gemcitabine, and dose expansion. For monotherapy dose escalation, patients with CLDN18.2+ gastric, GEJ, pancreatic, mucinous ovarian, and biliary tract cancers who have exhausted or are ineligible for the current standard of care are eligible. CLDN18.2 positivity is defined as intermediate/strong staining intensity in ≥50% of tumor cells evaluated using a validated immunohistochemistry assay. Doses of BNT141 are escalated in up to 8 planned dose levels (DLs) until the maximum tolerated dose (MTD) is reached. For combination dose escalation, patients with advanced CLDN18.2+ pancreatic adenocarcinoma or cholangiocarcinoma who are eligible for treatment with nab-paclitaxel/gemcitabine will be included. Combination therapy will start at the first safe DL where the target antibody concentration is reached during monotherapy. Combination dose escalation will continue in parallel with the monotherapy part and will define the recommended Phase II dose (RP2D). For both parts, up to 10 additional patients may be enrolled at the MTD level to collect further safety and PK/PD data. For dose expansion, 2 cohorts of patients with CLDN18.2+ pancreatic adenocarcinoma or cholangiocarcinoma will receive combination therapy (nab-paclitaxel/gemcitabine) together with BNT141 at the defined RP2D. The study was initiated in January 2022 and recruitment is ongoing in the USA and Canada. Sites in Spain, Portugal, Germany, Denmark, Netherlands and the UK will be opened in 2023. Clinical trial information: NCT04683939 ." @default.
• W4379283222 created "2023-06-05" @default.
• W4379283222 creator A5000036560 @default.
• W4379283222 creator A5000574001 @default.
• W4379283222 creator A5001209967 @default.
• W4379283222 creator A5022022603 @default.
• W4379283222 creator A5022467575 @default.
• W4379283222 creator A5026882542 @default.
• W4379283222 creator A5040306664 @default.
• W4379283222 creator A5040688276 @default.
• W4379283222 creator A5040756533 @default.
• W4379283222 creator A5044493081 @default.
• W4379283222 creator A5045951746 @default.
• W4379283222 creator A5056045552 @default.
• W4379283222 creator A5057151351 @default.
• W4379283222 creator A5059035314 @default.
• W4379283222 creator A5064548744 @default.
• W4379283222 creator A5071219496 @default.
• W4379283222 creator A5073134832 @default.
• W4379283222 creator A5075617216 @default.
• W4379283222 creator A5077991404 @default.
• W4379283222 creator A5084349853 @default.
• W4379283222 date "2023-06-01" @default.
• W4379283222 modified "2023-10-15" @default.
• W4379283222 title "A phase I/II dose escalation and expansion trial to evaluate safety and preliminary efficacy of BNT141 in patients with claudin-18.2-positive solid tumors." @default.
• W4379283222 doi "https://doi.org/10.1200/jco.2023.41.16_suppl.tps2670" @default.
• W4379283222 hasPublicationYear "2023" @default.
• W4379283222 type Work @default.
• W4379283222 citedByCount "1" @default.
• W4379283222 countsByYear W43792832222023 @default.
• W4379283222 crossrefType "journal-article" @default.
• W4379283222 hasAuthorship W4379283222A5000036560 @default.
• W4379283222 hasAuthorship W4379283222A5000574001 @default.
• W4379283222 hasAuthorship W4379283222A5001209967 @default.
• W4379283222 hasAuthorship W4379283222A5022022603 @default.
• W4379283222 hasAuthorship W4379283222A5022467575 @default.
• W4379283222 hasAuthorship W4379283222A5026882542 @default.
• W4379283222 hasAuthorship W4379283222A5040306664 @default.
• W4379283222 hasAuthorship W4379283222A5040688276 @default.
• W4379283222 hasAuthorship W4379283222A5040756533 @default.
• W4379283222 hasAuthorship W4379283222A5044493081 @default.
• W4379283222 hasAuthorship W4379283222A5045951746 @default.
• W4379283222 hasAuthorship W4379283222A5056045552 @default.
• W4379283222 hasAuthorship W4379283222A5057151351 @default.
• W4379283222 hasAuthorship W4379283222A5059035314 @default.
• W4379283222 hasAuthorship W4379283222A5064548744 @default.
• W4379283222 hasAuthorship W4379283222A5071219496 @default.
• W4379283222 hasAuthorship W4379283222A5073134832 @default.
• W4379283222 hasAuthorship W4379283222A5075617216 @default.
• W4379283222 hasAuthorship W4379283222A5077991404 @default.
• W4379283222 hasAuthorship W4379283222A5084349853 @default.
• W4379283222 hasConcept C126322002 @default.
• W4379283222 hasConcept C143998085 @default.
• W4379283222 hasConcept C159654299 @default.
• W4379283222 hasConcept C197934379 @default.
• W4379283222 hasConcept C203014093 @default.
• W4379283222 hasConcept C2776146153 @default.
• W4379283222 hasConcept C2776694085 @default.
• W4379283222 hasConcept C2778375690 @default.
• W4379283222 hasConcept C2780258809 @default.
• W4379283222 hasConcept C542903549 @default.
• W4379283222 hasConcept C71924100 @default.
• W4379283222 hasConceptScore W4379283222C126322002 @default.
• W4379283222 hasConceptScore W4379283222C143998085 @default.
• W4379283222 hasConceptScore W4379283222C159654299 @default.
• W4379283222 hasConceptScore W4379283222C197934379 @default.
• W4379283222 hasConceptScore W4379283222C203014093 @default.
• W4379283222 hasConceptScore W4379283222C2776146153 @default.
• W4379283222 hasConceptScore W4379283222C2776694085 @default.
• W4379283222 hasConceptScore W4379283222C2778375690 @default.
• W4379283222 hasConceptScore W4379283222C2780258809 @default.
• W4379283222 hasConceptScore W4379283222C542903549 @default.
• W4379283222 hasConceptScore W4379283222C71924100 @default.
• W4379283222 hasIssue "16_suppl" @default.
• W4379283222 hasLocation W43792832221 @default.
• W4379283222 hasOpenAccess W4379283222 @default.
• W4379283222 hasPrimaryLocation W43792832221 @default.
• W4379283222 hasRelatedWork W2024219304 @default.
• W4379283222 hasRelatedWork W2026791198 @default.
• W4379283222 hasRelatedWork W2100029565 @default.
• W4379283222 hasRelatedWork W2113566724 @default.
• W4379283222 hasRelatedWork W2139955290 @default.
• W4379283222 hasRelatedWork W2300929849 @default.
• W4379283222 hasRelatedWork W2351131972 @default.
• W4379283222 hasRelatedWork W3192482352 @default.
• W4379283222 hasRelatedWork W4254666574 @default.
• W4379283222 hasRelatedWork W4304587229 @default.
• W4379283222 hasVolume "41" @default.
• W4379283222 isParatext "false" @default.
• W4379283222 isRetracted "false" @default.
• W4379283222 workType "article" @default.